Theratechnologies Resubmits Supplemental Biologics License Application To FDA For F8 Formulation Of Tesamorelin

The FDA will review the updated sBLA within four months of submission. Theratechnologies therefore expects a decision around the end of March 2025. The new formulation is patent protected in the U.S. until 2033.